Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.

Background: Large-scale vaccination against COVID-19 is being implemented in many countries with CoronaVac, an inactivated vaccine. We aimed to assess the immune persistence of a two-dose schedule of CoronaVac, and the immunogenicity and safety of a third dose of CoronaVac, in healthy adults aged 18...

Descripción completa

Detalles Bibliográficos

Publicado en:	Lancet Infectious Diseases Vol. 22; no. 4; pp. 483 - 496
Autores principales:	Zeng, Gang, Wu, Qianhui, Pan, Hongxing, Li, Minjie, Yang, Juan, Wang, Lin, Wu, Zhiwei, Jiang, Deyu, Deng, Xiaowei, Chu, Kai, Zheng, Wen, Wang, Lei, Lu, Wanying, Han, Bihua, Zhao, Yuliang, Zhu, Fengcai, Yu, Hongjie, Yin, Weidong
Formato:	research Journal Article
Publicado:	Elsevier B.V. Apr2022
Acceso en línea:	Ver este registro en EBSCOhost